HSDT - Helius Medical Technologies Inc Stock Price, Fair Value and News

1.48USD-0.04 (-2.63%)Market Closed

Market Summary

USD1.48-0.04

Market Closed

-2.63%

HSDT Stock Price

View Fullscreen

HSDT RSI Chart

HSDT Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

5.61

EV/EBITDA

-0.02

Price/Free Cashflow

-0.37

HSDT Price/Sales (Trailing)

HSDT Profitability

EBT Margin

-1328.14%

Return on Equity

-446.73%

Return on Assets

-154.11%

Free Cashflow Yield

-273.54%

HSDT Fundamentals

HSDT Revenue

Revenue (TTM)

668.0K

Rev. Growth (Yr)

21.62%

Rev. Growth (Qtr)

0.75%

HSDT Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

-0.88%

Earnings Growth (Qtr)

-140.77%

Breaking Down HSDT Revenue

Last 7 days

-9.2%

Last 30 days

-71.4%

Last 90 days

-74.7%

Trailing 12 Months

-81.6%

How does HSDT drawdown profile look like?

HSDT Financial Health

Current Ratio

3.51

HSDT Investor Care

Shares Dilution (1Y)

348.31%

Diluted EPS (TTM)

-12.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	668.0K	0	0	0
2023	708.0K	845.0K	792.0K	644.0K
2022	628.0K	676.0K	763.0K	787.0K
2021	538.5K	476.5K	454.5K	522.0K
2020	1.0M	641.5K	622.5K	661.5K
2019	732.6K	987.3K	1.2M	1.5M
2018	0	353.1K	415.6K	478.0K
2016	103.3K	165.8K	228.2K	290.7K
2015	0	0	0	0
2014	807.4K	0	0	0
2013	4.3M	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Helius Medical Technologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 14, 2023	andreeff dane	bought	40,475	8.095	5,000	president and ceo
Dec 01, 2023	andreeff dane	bought	12,934	6.448	2,006	president and ceo
Dec 01, 2023	andreeff dane	bought	4,146	6.448	643	president and ceo
Nov 30, 2023	andreeff dane	bought	12,740	6.3704	2,000	president and ceo
Nov 30, 2023	andreeff dane	bought	4,083	6.3704	641	president and ceo
Aug 30, 2023	andreeff dane	bought	38,211	7.6423	5,000	president and ceo
Aug 28, 2023	andreeff dane	bought	32,338	6.3684	5,078	president and ceo
May 24, 2023	buckman paul	acquired	-	-	83,054	-
May 24, 2023	straw edward m	acquired	-	-	83,054	-
May 24, 2023	walter blane	acquired	-	-	83,054	-

Which funds bought or sold HSDT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-9.00	23.00	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	432	432	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-28.12	-5,364	5,842	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	64,352	64,352	-%
May 14, 2024	TORONTO DOMINION BANK	unchanged	-	-15.00	41.00	-%
May 13, 2024	UBS Group AG	sold off	-100	-1,736	-	-%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-186	489	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	20.00	-5.00	35.00	-%
May 10, 2024	BlackRock Inc.	sold off	-100	-40,735	-	-%

Are Funds Buying or Selling HSDT?

Are funds buying HSDT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HSDT

No. of Funds

Unveiling Helius Medical Technologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 14, 2024	intracoastal capital, llc	4.99%	90,288	SC 13G
Feb 13, 2024	avid fund services, llc	9.90%	50,000	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	0.1%	590	SC 13G/A
Feb 05, 2024	hudson bay capital management lp	7.86%	60,422	SC 13G/A
Oct 31, 2023	avid fund services, llc	9.6%	54,504	SC 13G
Sep 11, 2023	andreeff dane	10.5%	59,597	SC 13D/A
Feb 08, 2023	intracoastal capital, llc	5.1%	1,500,000	SC 13G/A
Feb 08, 2023	hudson bay capital management lp	9.68%	3,021,088	SC 13G
Aug 15, 2022	intracoastal capital, llc	8.4%	2,500,000	SC 13G
Feb 14, 2022	columbus capital management llc	8.5%	324,684	SC 13G/A

Recent SEC filings of Helius Medical Technologies Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	SC 13G	Major Ownership Report
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
May 08, 2024	424B4	Prospectus Filed
May 06, 2024	EFFECT	EFFECT
May 06, 2024	8-K	Current Report
Apr 26, 2024	S-1/A	Initial Public Offering
Apr 15, 2024	S-1	Initial Public Offering
Apr 05, 2024	8-K	Current Report

Peers (Alternatives to Helius Medical Technologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Helius Medical Technologies Inc News

Latest updates

Helius Medical Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.7%	135,000	134,000	143,000	256,000	111,000	282,000	196,000	119,000	190,000	258,000	109,000	71,000	84,000	190,500	131,000	133,000	207,000	151,500	150,000	518,000	677,000
Gross Profit	-72.7%	12,000	44,000	-44,000	72,000	-11,000	132,000	95,000	31,000	66,000	128,500	23,000	4,000	69,000	-10,500	109,000	69,000	106,000	-157,000	61,000	306,000	441,000
Operating Expenses	49.7%	3,428,000	2,290,000	3,109,000	3,291,000	3,799,000	2,801,000	4,948,000	3,461,000	4,630,000	4,230,500	4,396,000	6,170,000	3,570,000	2,991,500	3,769,000	3,791,000	4,108,000	5,468,000	5,797,000	6,120,000	7,262,000
S&GA Expenses	61.3%	2,633,000	1,632,000	2,196,000	2,569,000	2,874,000	1,967,000	3,393,000	2,461,000	2,819,000	2,376,000	2,859,000	4,744,000	2,197,000	2,088,500	2,370,000	2,394,000	2,862,000	3,805,000	4,291,000	3,845,000	4,581,000
R&D Expenses	21.2%	788,000	650,000	722,000	684,000	886,000	794,000	751,000	953,000	1,764,000	1,808,000	1,489,000	1,377,000	1,316,000	827,000	1,327,000	1,308,000	1,120,000	1,599,000	1,506,000	2,275,000	2,681,000
EBITDA Margin	3.4%	-13.21	-13.67	-15.98	-11.85	-17.17	-17.79	-23.63	-26.67	-28.70	-34.52	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-140.8%	-2,516,000	-1,045,000	-3,663,000	-1,648,000	-2,494,000	-4,886,000	-1,030,000	-3,810,000	-4,346,000	-	-4,687,000	-5,981,000	-	-	-	-	-	-	-	-	-
EBT Margin	3.4%	-13.28	-13.74	-16.02	-11.90	-17.26	-17.88	-23.76	-26.82	-28.87	-34.74	-	-	-	-	-	-	-	-	-	-	-
Net Income	-140.8%	-2,516,000	-1,045,000	-3,663,000	-1,648,000	-2,494,000	-4,886,000	-1,030,000	-3,810,000	-4,346,000	-4,102,000	-4,687,000	-5,981,000	-3,362,000	-2,535,000	-3,477,000	-3,361,000	-4,757,000	-5,331,000	-5,588,000	-186,000	1,324,000
Net Income Margin	3.4%	-13.28	-13.74	-16.02	-11.90	-17.26	-17.88	-17.42	-25.07	-30.44	-34.74	-36.45	-32.22	-	-	-	-	-	-	-	-	-
Free Cashflow	-47.6%	-3,006,000	-2,037,000	-2,458,000	-2,741,000	-3,209,000	-2,141,000	-3,828,000	-3,674,000	-4,684,000	-3,468,000	-3,265,000	-3,769,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-25.2%	5,757	7,692	8,854	10,753	13,755	17,287	18,859	6,546	9,618	14,102	7,879	10,717	14,664	6,547	6,026	8,704	8,461	10,347	12,880	18,197	22,498
Current Assets	-25.7%	5,524	7,438	8,576	10,265	13,209	16,697	18,217	5,064	8,026	12,594	6,238	8,985	12,863	4,685	4,136	6,743	5,875	7,241	11,228	16,529	20,831
Cash Equivalents	-30.8%	3,600	5,200	6,596	8,600	11,300	14,549	16,658	3,273	6,310	11,005	4,700	7,400	11,397	3,331	2,680	5,264	4,360	5,459	9,019	14,311	18,656
Inventory	-16.0%	384	457	521	563	617	589	609	577	520	476	538	507	484	389	572	570	594	598	1,289	902	731
Net PPE	-2.2%	174	178	182	345	354	347	348	365	380	409	451	449	477	486	463	478	678	712	725	711	693
Goodwill	-	-	-	-	-	-	-	-	753	777	763	762	783	769	759	725	710	686	1,242	-	-	-
Liabilities	-29.4%	3,771	5,342	5,833	6,181	7,688	9,136	5,898	2,044	2,488	2,846	2,842	2,350	2,766	2,676	2,829	2,308	3,252	4,512	4,058	5,415	10,480
Current Liabilities	-16.1%	1,576	1,879	1,435	1,524	1,789	1,988	1,200	1,777	2,199	2,653	2,642	2,137	2,534	2,424	2,565	2,027	2,617	3,802	3,547	4,861	9,883
Shareholder's Equity	-15.5%	1,986	2,350	3,021	4,572	6,067	8,151	12,961	4,502	7,130	11,256	5,037	8,367	11,898	3,871	3,197	6,396	5,209	5,835	8,822	12,782	12,018
Retained Earnings	-1.5%	-162,473	-160,000	-158,900	-155,249	-153,601	-151,107	-146,221	-145,200	-141,381	-137,035	-132,900	-128,200	-122,265	-118,903	-116,368	-112,891	-109,530	-104,773	-99,442	-93,854	-93,668
Additional Paid-In Capital	1.1%	164,843	162,979	162,391	160,443	160,023	159,645	159,386	150,665	149,834	149,412	139,093	138,023	135,388	123,872	120,257	119,763	114,967	111,509	108,997	107,437	106,363
Shares Outstanding	24.2%	887	715	688	565	564	564	171	77.00	76.00	76.00	47.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,260	-	-	-	4,729	-	-	-	37,215	-	-	-	17,405	-	-	-	41,929	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-47.5%	-3,001	-2,034	-2,452	-2,740	-3,190	-2,143	-3,821	-3,664	-4,682	-3,463	-3,235	-3,769	-2,921	-2,171	-2,588	-3,228	-3,751	-4,539	-5,246	-4,414	-6,800
Share Based Compensation	0%	401	401	403	420	405	232	1,441	179	402	356	740	2,629	527	508	450	729	842	1,355	1,560	941	835
Cashflow From Investing	-66.7%	-5.00	-3.00	-6.00	-1.00	-19.00	2.00	-7.00	-10.00	4.00	-5.00	-30.00	-	-21.00	-49.00	-11.00	61.00	-10.00	-509	-56.00	-43.00	-161
Cashflow From Financing	135.2%	1,463	622	-	-	-	-	17,249	637	-17.00	9,773	519	-186	11,020	2,911	-	4,075	2,652	1,490	-	123	40.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HSDT Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Product sales, net	$ 124	$ 106
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Other revenue	$ 11	$ 5
Total revenue	135	111
Cost of revenue
Cost of revenue	$ 123	$ 122
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit (loss)	$ 12	$ (11)
Operating expenses
Selling, general and administrative expenses	2,633	2,874
Research and development expenses	788	886
Amortization expense	7	39
Total operating expenses	3,428	3,799
Loss from operations	(3,416)	(3,810)
Nonoperating income (expense)
Interest income (expense), net	(8)	100
Change in fair value of derivative liability	1,142	1,221
Foreign exchange loss	(288)	(5)
Other income, net	54
Nonoperating income, net	900	1,316
Loss before provision for income taxes	(2,516)	(2,494)
Provision for income taxes
Net loss	(2,516)	(2,494)
Other comprehensive income (loss)
Foreign currency translation adjustments	288	5
Comprehensive loss	$ (2,228)	$ (2,489)
Loss per share
Basic (in dollar per share)	$ (3.08)	$ (4.42)
Diluted (in dollar per share)	$ (3.08)	$ (4.42)
Weighted average number of common shares outstanding
Basic (in shares)	817,327	564,134
Diluted (in shares)	817,327	564,134

HSDT Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 3,638	$ 5,182
Accounts receivable, net	49	117
Other receivables	513	520
Inventory, net	384	457
Prepaid expenses and other current assets	940	1,162
Total current assets	5,524	7,438
Property and equipment, net	174	178
Intangible assets, net	17	24
Operating lease right-of-use asset, net	42	52
Total assets	5,757	7,692
Current liabilities
Accounts payable	814	531
Accrued and other current liabilities	674	1,260
Current portion of operating lease liabilities	46	45
Current portion of deferred revenue	42	43
Total current liabilities	1,576	1,879
Operating lease liabilities, net of current portion		12
Deferred revenue, net of current portion	115	128
Derivative liability	2,080	3,323
Total liabilities	3,771	5,342
Commitments and contingencies (Note 9)
Stockholders' equity
Class A common stock, $0.001 par value; 150,000,000 shares authorized; 887,847 and 714,590 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	164,843	162,979
Accumulated deficit	(162,473)	(159,957)
Accumulated other comprehensive loss	(385)	(673)
Total stockholders' equity	1,986	2,350
Total liabilities and stockholders' equity	$ 5,757	$ 7,692

About Helius Medical Technologies Inc

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

CEO	Mr. Dane Carl Andreeff
WEBSITE	https://heliusmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	26

Helius Medical Technologies Inc Frequently Asked Questions

What is the ticker symbol for Helius Medical Technologies Inc? What does HSDT stand for in stocks?

HSDT is the stock ticker symbol of Helius Medical Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Helius Medical Technologies Inc (HSDT)?

As of Fri May 17 2024, market cap of Helius Medical Technologies Inc is 3.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HSDT stock?

You can check HSDT's fair value in chart for subscribers.

What is the fair value of HSDT stock?

You can check HSDT's fair value in chart for subscribers. The fair value of Helius Medical Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Helius Medical Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HSDT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Helius Medical Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether HSDT is over valued or under valued. Whether Helius Medical Technologies Inc is cheap or expensive depends on the assumptions which impact Helius Medical Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HSDT.

What is Helius Medical Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HSDT's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 5.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HSDT PE ratio will change depending on the future growth rate expectations of investors.